Nov.16 -- Moderna Inc. reported its Covid-19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage clinical trial. Noubar Afeyan, Moderna co-founder and chairman, discusses the company's new data, distribution, plan for emergency use authorization and its advantage over a vaccine by Pfizer Inc. Afeyan spoke with Bloomberg's Emily Chang.